Chemistry:Cadonilimab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | AK104; AK-104 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody[1][2] developed to treat a variety of solid cancer types. In June 2022 it was approved in China "for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy".[3]
References
- ↑ Pang, Xinghua; Huang, Zhaoliang; Zhong, Tingting; Zhang, Peng; Wang, Zhongmin Maxwell; Xia, Michelle; Li, Baiyong (2023). "Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity". mAbs 15 (1): 2180794. doi:10.1080/19420862.2023.2180794. ISSN 1942-0862. PMID 36872527.
- ↑ Gao, Xiangyu; Xu, Nong; Li, Ziyu; Shen, Lin; Ji, Ke; Zheng, Zhong; Liu, Dan; Lou, Hanmei et al. (October 2023). "Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial". The Lancet Oncology 24 (10): 1134–1146. doi:10.1016/S1470-2045(23)00411-4. PMID 37797632.
- ↑ Keam, Susan J. (August 2022). "Cadonilimab: First Approval". Drugs 82 (12): 1333–1339. doi:10.1007/s40265-022-01761-9. PMID 35986837. https://figshare.com/articles/online_resource/Cadonilimab_First_Approval/20422560.
 |  |
